US 12,406,760 B2
Exercise safety prediction based on physiological conditions
Ashutosh Zade, San Diego, CA (US); Joon Bok Lee, Acton, MA (US); and Yibin Zheng, Hartland, WI (US)
Assigned to INSULET CORPORATION, Acton, MA (US)
Filed by INSULET CORPORATION, Acton, MA (US)
Filed on Jun. 7, 2022, as Appl. No. 17/834,332.
Claims priority of provisional application 63/197,613, filed on Jun. 7, 2021.
Prior Publication US 2022/0392603 A1, Dec. 8, 2022
Int. Cl. G16H 20/30 (2018.01); A61B 5/00 (2006.01); A61B 5/145 (2006.01); A61M 5/172 (2006.01); G16H 20/17 (2018.01)
CPC G16H 20/30 (2018.01) [A61B 5/0004 (2013.01); A61B 5/0022 (2013.01); A61B 5/14532 (2013.01); A61B 5/7267 (2013.01); A61B 5/7275 (2013.01); A61B 5/743 (2013.01); A61B 5/7475 (2013.01); A61M 5/1723 (2013.01); G16H 20/17 (2018.01)] 20 Claims
OG exemplary drawing
 
1. A wearable drug delivery device, comprising:
a processor,
a reservoir configured to contain insulin;
a pump mechanism communicatively coupled to the processor and fluidically coupled to the reservoir; and
a memory coupled to the processor and operable to store programming code that, when executed by the processor, causes the processor to:
use an insulin on board (IOB) curve in determining a basal dose of insulin to deliver to a wearer;
receive data indicative of a physiological condition of the wearer of the wearable drug delivery device;
evaluate the received data with relation to the wearer participating in exercise;
based on a result of the evaluation,
determine whether it is safe for the wearer to participate in exercise; and
output an exercise safety signal indicating a result of the determination of whether it is safe or unsafe for the wearer to participate in exercise; and
where the evaluation determines that the wearer is exercising,
lengthening the IOB curve, and
using the lengthened IOB curve to determine a next basal dose of insulin for the wearer.